• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2023 Results Above Company Guidance

    2/14/24 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    Company updates capital allocation priorities, announces dividend and provides initial outlook for Q1 and FY 2024

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2023 results slightly above its latest guidance.

    Executive Summary

    Q4 2023 vs. Prior-year Quarter

    Revenue

    $488.6 million; (6)%

    • (1)% FX impact or $(7.2) million
    • Rhyz revenue $65.1 million; 101%

    Earnings Per Share (EPS)

    $0.15 or $0.37 excluding restructuring and other charges, compared to $1.15 or $0.89 excluding restructuring and impairment charges and a favorable tax rate in Q4 22

    Customers

    977,039; (15)%

    Paid Affiliates

    166,886; (30)% or (13)% excluding an adjustment to eligibility requirements

    Sales Leaders

    44,059; (10)%

    Executive Summary

    2023 vs. 2022

    Revenue:

    $1.97 billion; (12)%

    • (3)% FX impact or $(60.4) million
    • Rhyz revenue $216.6 million; 41%

    Earnings Per Share (EPS):

    $0.17 or $1.85 excluding inventory write-off and other charges, compared to $2.07 or $2.90 excluding restructuring and impairment charges

    "While we continue to work toward our long-term vision of becoming the world's leading integrated beauty and wellness platform, our progress was impacted by persistent macro-economic pressures and disruptions associated with transforming our business," said Ryan Napierski, Nu Skin president and CEO. "This was particularly evident with our fourth quarter results, which were down in our Americas, South Korea and Europe & Africa segments. This was offset by seasonal promotions in Mainland China, stabilization in Japan and modest growth in our Hong Kong/Taiwan segment. In addition, we achieved strong growth in our Rhyz businesses, which accounted for 13 percent of our revenue in the fourth quarter.

    "We are committed to generating long-term enterprise value by repositioning our company to win in the rapidly evolving beauty and wellness industries by further transforming our core Nu Skin business and accelerating investment in our rapidly growing Rhyz ecosystem," continued Napierski. "To enhance this transformation, we are reassessing our approach to capital allocation to invest in long-term growth and business evolution. This initiative aims to grant us increased financial flexibility, enabling us to effectively seize forthcoming growth opportunities. This includes rebalancing our dividend payout ratio to be in line with or better than our industry peers. With the additional available capital, we will focus our investments relatively evenly across three key initiatives: 1) accelerating the growth opportunities in Rhyz; 2) facilitating a new market expansion model beginning with India anticipated in 2025; and 3) furthering the build-out of our digital-first affiliate opportunity platform. While we continue to navigate the challenges of a business transformation amid these disruptive times, we have fine-tuned our strategy and remain confident in our ability to generate long-term growth and value for shareholders."

    Q4 2023 Year-over-year Operating Results

    Revenue

    $488.6 million compared to $522.3 million

    • (1)% FX impact or $(7.2) million
    • Rhyz revenue $65.1 million; 101%

    Gross Margin

    72.1% compared to 71.7%

    • Nu Skin business was 77.4% compared to 74.9%

    Selling Expenses

    37.1% compared to 38.5%

    • Nu Skin business was 40.8% compared to 40.5%

    G&A Expenses

    29.7% compared to 24.4%

    Operating Margin

    3.3% or 6.4% excluding restructuring and other charges compared to 5.3% or 8.8% excluding restructuring and impairment charges

    Other Expense

    $(6.7) million compared to $(3.1) million

    Income Tax Rate

    21.9% or 24.9% excluding restructuring and other charges compared to (134.9)% or (3.7)% excluding restructuring and impairment charges

    EPS

    $0.15 or $0.37 excluding restructuring and other charges compared to $1.15 or $0.89 excluding restructuring and impairment charges and a tax method change

    Stockholder Value

    Dividend Payments

    $19.3 million

    Stock Repurchases

    $0.0 million

    • $162.4 million remaining in authorization

    Q1 and Full-year 2024 Outlook

    Q1 2024 Revenue

    $400 to $435 million; (17)% to (10)%

    • Approximately (3) to (2)% FX impact

    Q1 2024 EPS

    $(0.07) to $0.03 or $0.00 to $0.10 non-GAAP

    2024 Revenue

    $1.73 to $1.87 billion; (12)% to (5)%

    • Approximately (1)% FX impact

    2024 EPS

    $0.75 to $1.15 or $0.95 to $1.35 non-GAAP

    "Our initial 2024 guidance assumes the global macro environment remains challenging in the near-term, improving throughout the year," said James D. Thomas, chief financial officer. "Our annual revenue guidance is $1.73 to $1.87 billion, with an approximate 1% foreign currency headwind. We anticipate reported EPS of $0.75 to $1.15 or adjusted earnings of $0.95 to $1.35, excluding charges associated with our extended restructuring plan. Our guidance reflects an anticipated higher global effective tax rate, primarily due to the expected geographical mix of earnings during the year. For the first quarter, we project revenue of $400 to $435 million, assuming a negative foreign currency impact of approximately 3%, with reported earnings per share of $(0.07) to $0.03 or $0.00 to $0.10 excluding restructuring charges."

    Dividend Payout

    The Nu Skin Enterprises board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 6, 2024, to shareholders of record on Feb. 26, 2024.

    Conference Call

    The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Feb. 28, 2024.

    About Nu Skin Enterprises Inc.

    The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by nearly 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro environment and the company's performance, growth and growth opportunities, shareholder value, financial flexibility, transformation, evolution, investments, initiatives, digital tools and initiatives, and new market expansion; projections regarding revenue, expenses, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "aim," "commit," "reposition," "anticipate," "accelerate," "project," "vision," "continue," "outlook," "guidance," "improve," "will," "would," "could," "may," "might," the negative of these words and other similar words.

    The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

    • any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
    • risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
    • economic conditions and events globally;
    • competitive pressures in the company's markets;
    • risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
    • adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
    • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
    • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
    • risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
    • uncertainties regarding the future financial performance of the businesses the company has acquired;
    • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
    • regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and
    • the company's future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets.

    The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

    Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

    Earnings per share, operating margin and income tax rate, each excluding inventory write-off charges, restructuring charges, and/or other charges, also are non-GAAP financial measures. Inventory write-off charges and restructuring charges are not part of the ongoing operations of our underlying business, and the legal accrual and non-recurring foreign tax charge that have been excluded in the non-GAAP financial measures are not typical for our ongoing operations. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.

    The following table sets forth revenue for the three-month periods ended December 31, 2023, and 2022 for each of our reportable segments (U.S. dollars in thousands):

    Three Months Ended

    December 31,

     

     

    Constant-Currency

     

    2023

     

    2022

     

    Change

     

    Change

    Nu Skin

    Americas

    $

    97,753

     

    $

    128,921

     

     

    (24)%

     

    (19)%

    Mainland China

     

    71,516

     

    73,935

     

     

    (3)%

     

    (2)%

    Southeast Asia/Pacific

     

    66,889

     

     

    76,606

     

     

    (13)%

     

    (12)%

    South Korea

     

    48,380

     

     

    60,029

     

     

    (19)%

     

    (22)%

    Japan

     

    50,966

     

     

    53,877

     

     

    (5)%

     

     

    (1)%

    Europe & Africa

     

    47,892

     

     

    55,337

     

     

    (13)%

     

    (18)%

    Hong Kong/Taiwan

     

    41,209

     

     

    39,789

     

     

    4%

     

    5%

    Nu Skin other

     

    (1,066)

     

     

    1,525

     

     

    (170)%

     

     

    (170)%

    Total Nu Skin

    423,539

    490,019

    (14)%

    (12)%

    Rhyz

    Manufacturing

    50,363

    29,560

    70%

    70%

    Rhyz other

    14,738

    2,761

    434%

    434%

    Total Rhyz

    65,101

    32,321

    101%

    101%

    Total

    $

    488,640

     

    $

    522,340

     

     

    (6)%

     

    (5)%

    The following table sets forth revenue for the years ended December 31, 2023, and 2022 for each of our reportable segments (U.S. dollars in thousands):

    Year Ended

    December 31,

     

     

    Constant-Currency

     

    2023

     

    2022

     

    Change

     

    Change

    Nu Skin

    Americas

    $

    398,222

     

    $

    508,537

     

     

    (22)%

     

    (18)%

    Mainland China

     

    298,079

     

    360,389

     

     

    (17)%

     

    (13)%

    Southeast Asia/Pacific

     

    267,206

     

     

    344,411

     

     

    (22)%

     

    (21)%

    South Korea

     

    236,099

     

     

    268,707

     

     

    (12)%

     

    (11)%

    Japan

     

    207,833

     

     

    224,896

     

     

    (8)%

     

     

    (1)%

    Europe & Africa

     

    192,352

     

     

    204,275

     

     

    (6)%

     

    (8)%

    Hong Kong/Taiwan

     

    153,589

     

     

    157,197

     

     

    (2)%

     

    1%

    Nu Skin other

     

    -858

     

     

    3,959

     

     

    (122)%

     

     

    (122)%

    Total Nu Skin

    1,752,522

    2,072,371

    (15)%

    (13)%

    Rhyz

    Manufacturing

    181,395

    149,458

    21%

    21%

    Rhyz other

    35,214

    3,830

    819%

    819%

    Total Rhyz

    216,609

    153,288

    41%

    41%

    Total

    $

    1,969,131

     

    $

    2,225,659

     

     

    (12)%

     

    (9)%

    The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended December 31, 2023, and 2022:

    Year Ended

    December 31,

    2023

     

    2022

    Change

    Customers

     

     

     

     

     

     

     

    Americas

     

    231,183

    299,287

    (23)%

    Mainland China

     

    207,276

    202,933

    2%

    Southeast Asia/Pacific

     

    106,471

    141,183

    (25)%

    South Korea

     

    103,151

    123,749

     

    (17)%

    Japan

     

    113,670

    119,152

    (5)%

    Europe & Africa

     

    163,178

    197,917

    (18)%

    Hong Kong/Taiwan

     

    52,110

    62,903

    (17)%

    Total Customers

    977,039

    1,147,124

    (15)%

    Paid Affiliates

     

     

     

     

     

     

     

    Americas

     

    31,910

    42,633

    (25)%

    Mainland China

     

    25,889

    23,436

    10%

    Southeast Asia/Pacific

     

    34,404

    38,653

    (11)%

    South Korea(1)

     

    22,166

    45,058

    (51)%

    Japan(1)

     

    22,417

    38,021

    (41)%

    Europe & Africa(1)

     

    18,888

    31,869

    (41)%

    Hong Kong/Taiwan(1)

     

    11,212

    17,286

    (35)%

    Total Paid Affiliates

    166,886

    236,956

    (30)%

    Sales Leaders

     

     

     

     

     

     

     

    Americas

     

    7,126

    9,594

    (26)%

    Mainland China

    11,296

    12,359

    (9)%

    Southeast Asia/Pacific

     

    6,418

    6,999

    (8)%

    South Korea

     

    5,249

    6,094

    (14)%

    Japan

     

    7,086

    5,936

    19%

    Europe & Africa

     

    3,968

    4,740

    (16)%

    Hong Kong/Taiwan

     

    2,916

    3,015

    (3)%

    Total Sales Leaders

    44,059

    48,737

    (10)%

    (1) The December 31, 2023, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters. We estimate the change in eligibility requirements resulted in a reduction of approximately 14 thousand, 15 thousand, 6 thousand and 3 thousand for South Korea, Japan, Europe & Africa and Hong Kong/Taiwan, respectively.

    • "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
    • "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.
    • "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

    NU SKIN ENTERPRISES, INC.

    Consolidated Statements of Income (Unaudited)

    (U.S. dollars in thousands, except per share amounts)

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2023

     

    2022

     

    2023

     

    2022

    Revenue

    $

    488,640

     

     

    $

    522,340

     

     

    $

    1,969,131

     

     

    $

    2,225,659

     

    Cost of sales

     

    136,215

     

     

     

    147,816

     

     

     

    611,850

     

     

     

    630,915

     

    Gross profit

     

    352,425

     

     

     

    374,524

     

     

     

    1,357,281

     

     

     

    1,594,744

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

    Selling expenses

     

    181,326

     

     

     

    201,031

     

     

     

    742,365

     

     

     

    879,634

     

    General and administrative expenses

     

    145,033

     

     

     

    127,664

     

     

     

    546,858

     

     

     

    555,769

     

    Restructuring and impairment expenses

    10,003

     

    18,370

     

    19,790

     

    48,494

     

    Total operating expenses

     

    336,362

     

     

     

    347,065

     

     

     

    1,309,013

     

     

     

    1,483,897

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating income (loss)

     

    16,063

     

     

     

    27,459

     

     

     

    48,268

     

     

     

    110,847

     

    Other income (expense), net

     

    (6,735

    )

     

     

    (3,104

    )

     

     

    (21,690

    )

     

     

    (21,877

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Income (loss) before provision for income taxes

     

    9,328

     

     

     

    24,355

     

     

     

    26,578

     

     

     

    88,970

     

    Provision (benefit) for income taxes

     

    2,046

     

     

     

    (32,860

    )

     

     

    17,983

     

     

     

    (15,808

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss)

    $

    7,282

     

     

    $

    57,215

     

     

    $

    8,595

     

     

    $

    104,778

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss) per share:

     

     

     

     

     

     

     

     

     

     

    Basic

    $

    0.15

     

     

    $

    1.16

     

     

    $

    0.17

     

     

    $

    2.10

     

    Diluted

    $

    0.15

     

     

    $

    1.15

     

     

    $

    0.17

     

     

    $

    2.07

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000s):

     

     

     

     

     

     

     

     

     

     

    Basic

     

    49,411

     

     

     

    49,452

     

     

     

    49,711

     

     

     

    50,002

     

    Diluted

     

    49,479

     

     

     

    49,783

     

     

     

    49,860

     

     

     

    50,525

     

    NU SKIN ENTERPRISES, INC.

    Consolidated Balance Sheets (Unaudited)

    (U.S. dollars in thousands)

     

     

     

     

     

    December 31,

    2023

     

    December 31,

    2022

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    256,057

     

     

    $

     

    264,725

     

    Current investments

     

    11,759

     

     

     

     

    13,784

     

    Accounts receivable, net

     

    72,879

     

     

     

     

    47,360

     

    Inventories, net

     

    279,978

     

     

     

     

    346,183

     

    Prepaid expenses and other

     

    81,198

     

     

     

     

    87,816

     

    Total current assets

     

    701,871

     

     

     

     

    759,868

     

     

     

     

     

     

     

    Property and equipment, net

     

    432,965

     

     

     

     

    444,806

     

    Operating lease right-of-use assets

    90,107

     

     

    98,734

     

    Goodwill

     

    230,768

     

     

     

     

    206,432

     

    Other intangible assets, net

     

    105,309

     

     

     

     

    66,701

     

    Other assets

     

    245,443

     

     

     

     

    244,429

     

    Total assets

    $

    1,806,463

     

     

    $

     

    1,820,970

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

    Accounts payable

    $

    43,505

     

     

    $

     

    53,963

     

    Accrued expenses

     

    260,366

     

     

     

     

    280,280

     

    Current portion of long-term debt

     

    25,000

     

     

     

     

    25,000

     

    Total current liabilities

     

    328,871

     

     

     

     

    359,243

     

     

    Operating lease liabilities

     

    70,943

     

     

     

     

    76,540

     

    Long-term debt

     

    478,040

     

     

     

     

    377,466

     

    Other liabilities

     

    106,641

     

     

     

     

    110,425

     

    Total liabilities

     

    984,495

     

     

     

     

    923,674

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

    Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued

     

    91

     

     

     

     

    91

     

    Additional paid-in capital

     

    621,853

     

     

     

     

    613,278

     

    Treasury stock, at cost – 41.1 million and 41.1 million shares

     

    (1,570,440

    )

     

     

     

    (1,569,061

    )

    Accumulated other comprehensive loss

     

    (100,006

    )

     

     

     

    (86,509

    )

    Retained earnings

     

    1,870,470

     

     

     

     

    1,939,497

     

    Total stockholders' equity

     

    821,968

     

     

     

     

    897,296

     

    Total liabilities and stockholders' equity

    $

    1,806,463

     

     

    $

    $

    1,820,970

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Operating Margin Excluding Impact of Certain Charges to GAAP Operating Margin

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended

    December 31,

     

    Year ended

    December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Operating Income

     

    $

    16,063

     

     

    $

    27,459

     

     

    $

    48,268

     

     

    $

    110,847

     

    Impact of inventory write-off

     

     

    -

     

     

     

    -

     

     

     

    65,728

     

     

     

    26,905

     

    Impact of restructuring and impairment

     

     

    10,003

     

     

     

    18,370

     

     

     

    19,790

     

     

     

    48,494

     

    Impact of other charges(2)

     

     

    5,260

     

     

     

    -

     

     

     

    5,260

     

     

     

    -

     

    Adjusted operating income

     

    $

    31,326

     

     

    $

    45,829

     

     

    $

    139,046

     

     

    $

    186,246

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin

     

     

    3.3

    %

     

     

    5.3

    %

     

     

    2.5

    %

     

     

    5.0

    %

    Operating margin, excluding impact of certain charges

     

     

    6.4

    %

     

     

    8.8

    %

     

     

    7.1

    %

     

     

    8.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    488,640

     

     

    $

    522,340

     

     

    $

    1,969,131

     

     

    $

    2,225,659

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended

    December 31,

     

    Year ended

    December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Provision (benefit) for income taxes

     

    $

    2,046

     

     

    $

    (32,860

    )

     

    $

    17,983

     

     

    $

    (15,808

    )

    Impact of certain charges on provision for income taxes

     

     

    4,081

     

     

     

    31,284

     

     

     

    7,324

     

     

     

    42,838

     

    Provision for income taxes, excluding impact of certain charges

     

    $

    6,127

     

     

    $

    (1,576

    )

     

    $

    25,307

     

     

    $

    27,030

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Income before provision for income taxes

     

     

    9,328

     

     

     

    24,355

     

     

     

    26,578

     

     

     

    88,970

     

    Impact of inventory write-off

     

     

    -

     

     

     

    -

     

     

     

    65,728

     

     

     

    26,905

     

    Impact of restructuring and impairment

     

     

    10,003

     

     

     

    18,370

     

     

     

    19,790

     

     

     

    48,494

     

    Impact of other charges(2)

     

     

    5,260

     

     

     

    -

     

     

     

    5,260

     

     

     

    -

     

    Impact of charges associated with our exit from Grow Tech:

     

     

     

     

     

     

     

     

     

     

     

     

    Unrealized investment loss

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    9,009

     

    Income before provision for income taxes, excluding impact of certain charges

     

    $

    24,591

     

     

    $

    42,725

     

     

    $

    117,356

     

     

    $

    173,378

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Effective tax rate

     

     

    21.9

    %

     

     

    (134.9

    )%

     

     

    67.7

    %

     

     

    (17.8

    )%

    Effective tax rate, excluding impact of certain charges

     

     

    24.9

    %

     

     

    (3.7

    )%

     

     

    21.6

    %

     

     

    15.6

    %

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended

    December 31,

     

    Year ended

    December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Net income

     

    $

    7,282

     

     

    $

    57,215

     

     

    $

    8,595

     

     

    $

    104,778

     

    Impact of restructuring and inventory write-off expense:

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring and impairment

     

     

    10,003

     

     

     

    18,370

     

     

     

    19,790

     

     

     

    48,494

     

    Inventory write-off

     

     

    -

     

     

     

    -

     

     

     

    65,728

     

     

     

    26,905

     

    Tax impact

     

     

    (3,088

    )

     

     

    903

     

     

     

    (6,331

    )

     

     

    (9,566

    )

    Impact of other charges: (2)

     

     

     

     

     

     

     

     

     

     

     

     

    Impact of other charges

     

     

    5,260

     

     

     

     

     

     

    5,260

     

     

     

     

    Tax impact

     

     

    (993

    )

     

     

    -

     

     

     

    (993

    )

     

     

    -

     

    Impact of charges associated with our exit from Grow Tech:

     

     

     

     

     

     

     

     

     

     

     

     

    Unrealized loss on investment

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    9,009

     

    Tax impact

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (1,085

    )

    Tax impact

     

     

    -

     

     

     

    (32,187

    )

     

     

    -

     

     

     

    (32,187

    )

    Adjusted net income

     

    $

    18,464

     

     

    $

    44,301

     

     

    $

    92,049

     

     

    $

    146,348

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share

     

    $

    0.15

     

     

    $

    1.15

     

     

    $

    0.17

     

     

    $

    2.07

     

    Diluted earnings per share, excluding impact of certain charges

     

    $

    0.37

     

     

    $

    0.89

     

     

    $

    1.85

     

     

    $

    2.90

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000)

     

     

    49,479

     

     

     

    49,783

     

     

     

    49,860

     

     

     

    50,525

     

    (2) Other charges consist of a legal contingency ($3.0 million) and a non-recurring foreign tax charge ($2.3 million) that were recorded in the fourth quarter of 2023.

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

    Year ended

    December 31,

     

     

    2024 - Low-end

     

    2024 High-end

     

    2024 - Low-end

     

    2024 High-end

    Earnings Per Share

     

    $

    (0.07

    )

     

    $

    0.03

     

     

    $

    0.75

     

     

    $

    1.15

     

    Impact of restructuring expense:

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring

     

     

    0.10

     

     

     

    0.10

     

     

     

    0.30

     

     

     

    0.30

     

    Tax impact

     

     

    (0.03

    )

     

     

    (0.03

    )

     

     

    (0.10

    )

     

     

    (0.10

    )

    Adjusted EPS

     

    $

    -

     

     

    $

    0.10

     

     

    $

    0.95

     

     

    $

    1.35

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240214526617/en/

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

    Breakthrough intelligent platform measures skin carotenoid levels for antioxidant insights in just 15 seconds, empowering consumers to take control of their nutritional wellness Nu Skin Enterprises Inc. (NYSE:NUS), the world's #1 company for beauty and wellness device systems,* today announced the general consumer availability in the U.S. of Prysm iO™, a breakthrough intelligent nutritional wellness platform designed to deliver a better understanding of how daily nutrition and supplement routines support overall wellness. Prysm iO will launch for consumers in other Nu Skin markets in the coming months. This press release features multimedia. View the full release here: https://www.busine

    4/2/26 4:25:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nu Skin Enterprises Inc.

    DEFA14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    4/3/26 2:32:11 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form DEF 14A filed by Nu Skin Enterprises Inc.

    DEF 14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    4/3/26 2:28:12 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/27/26 4:34:56 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lantz Chelsea K

    3 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/30/26 5:57:22 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Woodbury Edwina D was granted 14 shares, increasing direct ownership by 0.03% to 42,993 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/12/26 5:03:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP, President of Global Sales Keisel Justin S was granted 47,059 shares, increasing direct ownership by 42% to 160,170 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/9/26 6:14:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal ca

    2/12/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care